Press Release

J.P. Morgan hosts third Global Healthcare Shanghai Conference

Shanghai, October 16, 2023 – J.P. Morgan will host its third Global Healthcare Shanghai Conference on October 17.

Drawing on J.P. Morgan's deep global healthcare investment expertise, the conference will bring together leading healthcare experts and business leaders from across the globe, to discuss topics including the outlook for global healthcare, M&A and investment trends within the sector, as well as new technology shaping the next generation of life science.

Mark Leung, CEO of J.P. Morgan China, said: “J.P. Morgan is pleased to have the opportunity to have witnessed, participated in and facilitated the growth of this key sector in China. Although the primary and secondary healthcare markets are still facing challenges and pressures, in the post-pandemic era, thanks to favorable policy margins, improvement in corporate profits and continuous innovation, China's healthcare industry has ushered in new development opportunities. We are upbeat about the healthcare market in China, and are committed to providing differentiated products and services to our clients, boosting the healthcare sector in China and delivering benefits to patients.”

As an important hub for the healthcare sector in China, Shanghai has significantly improved its innovation capabilities and seen an increasing inflow of talent over the years. According to statistics in 2022, Shanghai has raised the highest amount of funds in the biopharma sector and is home to the largest number of listed biopharma companies in China. It’s ranked No.1 nationwide in terms of biopharma FDI growth, the number of R&D headquarters of foreign biopharma companies and the number of domestic Category 1 innovative drugs. Shanghai has also attracted 280,000 biopharma professionals.

David Lau, co-head of China Investment Banking and co-head of Asia Healthcare Investment Banking at J.P. Morgan, said: " As the world's second largest healthcare market, the Chinese market is paying more and more attention to innovation. Innovation in the fields of biopharmaceuticals and medical devices is playing a core role in driving high-quality development of the Chinese market. High-intensity research and development continues to drive technologica progress, meet medical service needs, and promote changes in the industrial structure. At the same time, strengthening internationalization has become one of the key driving forces for promoting innovation. As China's healthcare industry continues to evolve, companies with innovation capabilities, differentiated products and the ability to address unmet clinical needs will achieve long-term growth. As one of the leading investment banks in the global and China’s healthcare industry, J.P. Morgan will continue to strengthen its healthcare investment banking services onshore and offshore to better suppor our clients."

J.P. Morgan is a leading financial institution in the healthcare industry globally and the host of the world’s largest healthcare investment symposium – the J.P. Morgan Healthcare Conference, held in San Francisco every year. This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. This year, in its 41st edition, the conference brought together more than 8,000 investors, industry professionals, senior government officials and 550 global healthcare companies, ranging from Fortune 100 corporations to small-cap and emerging private companies, to discuss the latest market trends and medical innovations.

About JPMorgan Chase & Co.

JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at

J.P. Morgan in China

J.P. Morgan has been doing business in China since 1921. J.P. Morgan’s integrated financial services include investment and corporate banking, payments, markets, sales and research, securities services, commercial banking and asset management. Today, the firm serves Chinese and international corporations, financial institutions and government agencies through our network across China.